A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Elizabeth A. Raetz, William L. Carroll, Eleny Romanos‐Sirakis et al.|Journal of Pediatric Hematology/Oncology|2013

Cited by 41